News

A form of CAR T cell therapy can find and destroy the cancer-driving stem cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while leaving healthy blood cells unharmed, in new research led by UCL and University of Oxford researchers.

Researchers at UCL and the Francis Crick Institute have identified 14 proteins in the blood that can predict lung cancer risk more than five years before diagnosis.

The first full results have been announced from the NHS-Galleri trial, a study co-led by a UCL researcher looking into the use of a blood test to see if it can help the NHS to detect cancer early.

Many people with breast cancer can safely avoid chemotherapy with the use of a gene test, potentially sparing them from unnecessary side effects without increasing the risk of the cancer returning, a large international clinical trial led by UCL has found.

A new blood test could help doctors identify whether a treatment for advanced prostate cancer treatment is failing weeks earlier than current tests, according to a UK-wide study led by UCL researchers.

Three patients with light chain amyloidosis have been treated with CAR T cell therapy in the first European clinical trial testing the safety and efficacy of this immunotherapy in this patient group, led by UCL and UCLH researchers.

Lung cancer that spreads to other parts of the body spawns tumours with significant genetic changes, which then spread further and changed more as patients near the end of their lives, finds a new study led by researchers at UCL and the Francis Crick Institute.

Patients with a specific bowel cancer who were given short-course immunotherapy before surgery, instead of post-op chemotherapy, remained cancer-free after nearly three years of follow-up, according to new results from the NEOPRISM-CRC trial led by UCL and UCLH.

A new method making cancer cells more visible to the immune system could improve how well immunotherapy works against a range of different tumours, potentially leading to more effective treatment for patients, according to a new study led by a team of UCL researchers.

Clinician researchers at UCL and UCLH are leading a major UK clinical trial to test whether proton beam therapy (PBT) can significantly improve survival rates for patients with mesothelioma, a rare and aggressive cancer of the lining of the lung.

A major UK clinical trial co-led by researchers at UCL will test whether lower doses of common hormone therapies can treat advanced prostate cancer while reducing the severe side effects many patients experience.

A previously unknown chain of molecular signals that determines how strongly the body’s immune system responds to viral infection has been discovered by scientists at UCL and the University of Cologne.

Team REWIRE-CAN, led by Professor Bart Vanhaesebroeck of the UCL Cancer Institute, will receive up to $25m over approximately five years to take on the rewiring cancer cells challenge.

Survival rates for people with cholangiocarcinoma, a silent but deadly form of cancer originating in the bile ducts, are dismal and a new approach is needed, argues a panel of leading experts including a UCL researcher.

Professor Charles Swanton (UCL Cancer Institute) has been awarded the 2026 Sjöberg Prize for his groundbreaking work on how tumours evolve, helping to explain why cancer treatments sometimes fail and paving the way for more precise, personalised therapies.